Company intelligence / Profile preview
Scienture Holdings
New York, New York, United Statesscientureholdings.com ↗
- Ownership
- Public · SCNX
- Development stage
- Commercial
01
Overview
Scienture Holdings is focused on developing, bringing to market, and distributing novel specialty pharmaceutical products and operates a commercialized specialty product (Arbli™, losartan potassium oral suspension) and an integrated web-based pharmacy drug purchasing/trading platform, Trxade[1][4].
- Therapeutic areas
- Cardiovascular
- Modalities
- Small moleculePlatform/Service
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not explicitly stated; references to partnerships with specialty/international manufacturers for the Trxade platform
04
Financials
- Market cap
- $5.6M
- Total revenue
- $56.3K
- Enterprise value
- $-3.5B
Beyond the preview
Go deeper on Scienture Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scienture Holdings.